Composition including propionibacterium freudenreichii MJ2 strain-derived extracellular vesicles or chaperonin protein as active ingredient for prevention, alleviation, or treatment of rheumatoid arthritis
The use of extracellular vesicles or a 60 kDa chaperonin protein from Propionibacterium freudenreichii MJ2 strain in compositions addresses the limitations of current rheumatoid arthritis treatments by inhibiting osteoclast differentiation and inflammatory responses, offering a safe and effective therapeutic option.
Patent Information
- Application Number
- PCT/KR2023/017254
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-02
- Filing Date
- 2023-11-01
- Publication Date
- 2024-11-07
AI Technical Summary
Current treatments for rheumatoid arthritis, such as anti-rheumatic drugs and immunosuppressants, have limitations including side effects, high costs, and insufficient therapeutic efficacy, necessitating the development of new treatments that can effectively suppress symptoms while being safe and effective.
A pharmaceutical and food composition containing extracellular vesicles or a 60 kDa chaperonin protein derived from the Propionibacterium freudenreichii MJ2 strain, which inhibits osteoclast differentiation, inflammatory cytokine production, and bone erosion, thereby preventing and treating rheumatoid arthritis.
The composition effectively reduces osteoclast differentiation, inflammatory cytokine production, and bone erosion, providing a safe and effective treatment for rheumatoid arthritis by controlling excessive immune and inflammatory reactions.
Smart Images

Figure KR2023017254_07112024_PF_FP_ABST
Abstract
Description
Composition for preventing, improving or treating rheumatoid arthritis comprising extracellular vesicles or chaperonin proteins derived from Propionibacterium freudencii MJ2 strain as an active ingredient
[0001] The present invention relates to a composition for preventing, improving or treating rheumatoid arthritis, comprising an extracellular vesicle or chaperonin protein derived from the Propionibacterium freudencii MJ2 strain as an active ingredient.
[0002] Rheumatoid arthritis is a disease caused by inflammation of the synovial membrane, the tissue surrounding the joints. It can occur in almost any movable joint and is a chronic condition that progresses over months to years. Rheumatoid arthritis is caused by an immune system disorder and can affect various organs beyond the joints. However, the most common early symptoms include swelling and pain in the joints of the hands and feet, although symptoms can also appear in the knees, shoulders, elbows, and jaw joints. Furthermore, inflammation of the heart and blood vessels, as well as interstitial lung disease, are known to occur.
[0003] Osteoclasts are cells that destroy and resorb bone and exhibit multinucleated characteristics. Osteoclasts undergo abnormal differentiation in response to inflammation. They are induced by the inflammatory factor RANKL (Receptor activator of nuclear factor kappa-B ligand), which binds to RANK, a RANKL receptor on the surface of osteoclast precursor cells, thereby inducing their differentiation into osteoclasts. Therefore, inhibiting osteoclast differentiation could be a target for preventing and treating arthritis, and substances that inhibit osteoclast differentiation could be therapeutic agents for preventing or treating arthritis.
[0004] Current treatments for rheumatoid arthritis include antirheumatic drugs, nonsteroidal anti-inflammatory drugs, and immunosuppressants, which help prevent joint damage. While nonsteroidal anti-inflammatory drugs may provide pain relief, they fail to slow the progression of the disease and can cause gastrointestinal upset with long-term use. Immunosuppressants, such as TNF-α inhibitors, can cause side effects like latent tuberculosis. Despite improved efficacy compared to past treatments, current medications still face challenges, including side effects, high costs, and limited efficacy relative to long-term administration.
[0005] Therefore, there is a need to develop a new treatment that is safe and has excellent therapeutic effects while more effectively suppressing rheumatoid arthritis symptoms.
[0006] Meanwhile, extracellular vesicles (EVs) are membrane-shaped vesicles released from cells. They are composed of a double phospholipid membrane and contain nucleic acids, proteins, and lipids. Previously, these EVs were considered cell waste, but numerous studies have shown that they play a crucial role in cell-cell interactions, immune function, and the diagnosis of specific diseases. While EVs have been developed and used as disease biomarkers, research into leveraging their inherent efficacy to treat specific diseases remains insufficient. Furthermore, no studies have yet investigated the potential use of EVs derived from probiotic microorganisms as a treatment for rheumatoid arthritis.
[0007] Accordingly, the inventors of the present invention, while conducting research to develop a new treatment for rheumatoid arthritis, isolated extracellular vesicles from the Propionibacterium freudenneckii MJ2 strain isolated and identified by the inventors, and confirmed that the isolated extracellular vesicles and the chaperonin protein contained in the vesicles have an excellent effect of inhibiting osteoclast differentiation, and when administered to collagen-induced rheumatoid arthritis mice, they were able to effectively prevent, improve, and treat rheumatoid arthritis, thereby completing the present invention.
[0008] Accordingly, the purpose of the present invention is to provide a pharmaceutical composition for preventing or treating rheumatoid arthritis, which contains extracellular vesicles or 60 kDa chaperonin protein (Cpn60) derived from a strain of Propionibacterium freudenreichii as an active ingredient.
[0009] Another object of the present invention is to provide a food composition for preventing or improving rheumatoid arthritis, which contains extracellular vesicles or 60 kDa chaperonin protein (Cpn60) derived from a strain of Propionibacterium freudenreichii as an active ingredient.
[0010] In order to achieve the above-described purpose of the present invention, the present invention provides a pharmaceutical composition for preventing or treating rheumatoid arthritis, which contains extracellular vesicles or 60 kDa chaperonin protein (Cpn60) derived from a strain of Propionibacterium freudenreichii as an active ingredient.
[0011] In one embodiment of the present invention, the Propionibacterium freudenreichii may be a strain of Propionibacterium freudenreichiiMJ2 (Accession No. KCCM12272P).
[0012] In one embodiment of the present invention, the composition may have the activity of suppressing the expression of factors related to osteoclast differentiation; suppressing the production of inflammatory cytokines; suppressing TRAP (Tartrate-resistant acid phosphatase) activity in osteoclasts; increasing the expression of IL-10; improving bone erosion; or suppressing the production of collagen antigen-specific IgG, IgG1, IgG2a antibodies.
[0013] In one embodiment of the present invention, the extracellular vesicles are present in the composition at a concentration of 1 × 10 6 particles / mL to 1 × 10 8 It may be contained in an amount of particles / mL.
[0014] In one embodiment of the present invention, the extracellular vesicles may have an average particle diameter of 150 to 200 nm.
[0015] In addition, the present invention provides a food composition for preventing or improving rheumatoid arthritis, which contains extracellular vesicles or 60 kDa chaperonin protein (Cpn60) derived from a strain of Propionibacterium freudenreichii as an active ingredient.
[0016] In one embodiment of the present invention, the Propionibacterium freudenreichii may be a strain of Propionibacterium freudenreichiiMJ2 (Accession No. KCCM12272P).
[0017] In one embodiment of the present invention, the composition may have the activity of suppressing the expression of factors related to osteoclast differentiation; suppressing the production of inflammatory cytokines; suppressing TRAP (Tartrate-resistant acid phosphatase) activity in osteoclasts; increasing the expression of IL-10; improving bone erosion; or suppressing the production of collagen antigen-specific IgG, IgG1, IgG2a antibodies.
[0018] In one embodiment of the present invention, the extracellular vesicles are present in the composition at a concentration of 1 × 10 6 particles / mL to 1 × 10 8 It may be contained in an amount of particles / mL.
[0019] In one embodiment of the present invention, the extracellular vesicles may have an average particle diameter of 150 to 200 nm.
[0020] The extracellular vesicles and 60 kDa chaperonin protein (Cpn60) isolated from the Propionibacterium freudenreichii MJ2 strain of the present invention can suppress the expression of factors related to osteoclast differentiation, suppress the production of inflammatory cytokines, and have the characteristics of suppressing TRAP activity, increasing IL-10 expression, improving bone erosion, and suppressing the production of collagen antigen-specific IgG, IgG1, and IgG2a antibodies. In addition, since they do not cause cytotoxicity or hepatotoxicity and are thus stable in the body, they can be usefully used in the manufacture of pharmaceuticals and health functional foods for preventing, improving, or treating rheumatoid arthritis through controlling excessive immune responses and inflammatory responses.
[0021] Figure 1 shows a photograph of extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain of the present invention observed using a scanning electron microscope (SEM).
[0022] Figure 2 shows a photograph of extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain of the present invention observed using a transmission electron microscope (TEM).
[0023] Figure 3 shows the results of measuring extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain of the present invention using NTA (nanoparticle tracking analysis).
[0024] Figure 4 shows the results of analyzing whether extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain of the present invention have cytotoxicity.
[0025] Figure 5 shows the results of analyzing the osteoclast differentiation inhibitory activity of extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain of the present invention.
[0026] Figure 6 shows the results of confirming the inhibition activity of osteoclast differentiation inducing factor gene expression of extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain of the present invention.
[0027] Figure 7 shows the results of confirming the inhibition activity of the osteoclast differentiation inducing factor protein expression of extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain of the present invention.
[0028] Figure 8 shows the results of confirming the arthritis improvement efficacy of extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain of the present invention in a collagen-induced arthritis mouse model.
[0029] Figure 9 shows the results of measuring the level of hepatotoxicity indicators in a collagen-induced arthritis mouse model of extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain of the present invention.
[0030] Figure 10 shows the results of confirming the efficacy of extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain of the present invention in improving knee joint damage in a collagen-induced arthritis mouse model.
[0031] Figure 11 shows the results showing the effect of extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain of the present invention on reducing the concentration of collagen antigen-specific antibodies in a collagen-induced arthritis mouse model.
[0032] Figure 12 shows the results of confirming the effect of extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain of the present invention on reducing the expression of inflammatory cytokines and increasing the expression of anti-inflammatory cytokines in a collagen-induced arthritis mouse model.
[0033] Figure 13 shows the results of suppressing the gene expression of osteoclast differentiation inducing factors and increasing the gene expression of osteoclast differentiation inhibitory factors in a collagen-induced arthritis mouse model using extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain of the present invention.
[0034] Figure 14 shows the results of confirming the osteoclast differentiation inhibition activity of extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain of the present invention in a collagen-induced arthritis mouse model.
[0035] Figure 15 shows the results of synthesizing and separating and purifying a chaperonin protein derived from the Propionibacterium freudencii MJ2 strain of the present invention.
[0036] Figure 16 shows the results of analyzing whether the chaperonin protein derived from the Propionibacterium freudencii MJ2 strain of the present invention has cytotoxicity.
[0037] Figure 17 shows the results of osteoclast differentiation inhibition activity for the chaperonin protein derived from the Propionibacterium freudencii MJ2 strain of the present invention.
[0038] Figure 18 shows the results of gene expression inhibition activity of osteoclast differentiation inducing factors for the chaperonin protein derived from the Propionibacterium freudencii MJ2 strain of the present invention.
[0039] Figure 19 shows the results of confirming the arthritis improvement effect of the chaperonin protein derived from the Propionibacterium freudencii MJ2 strain of the present invention in a collagen-induced arthritis mouse model.
[0040] Figure 20 shows the results of measuring the level of hepatotoxicity indicators in a collagen-induced arthritis mouse model of a chaperonin protein derived from the Propionibacterium freudencii MJ2 strain of the present invention.
[0041] Figure 21 shows the results showing the effect of the chaperonin protein derived from the Propionibacterium freudencii MJ2 strain of the present invention on improving bone erosion in a collagen-induced arthritis mouse model.
[0042] Figure 22 shows the results showing the effect of the chaperonin protein derived from the Propionibacterium freudencii MJ2 strain of the present invention on reducing the concentration of collagen antigen-specific antibodies in a collagen-induced arthritis mouse model.
[0043] Figure 23 shows the results of confirming the effect of the chaperonin protein derived from the Propionibacterium freudencii MJ2 strain of the present invention on reducing the expression of inflammatory cytokines in a collagen-induced arthritis mouse model.
[0044] Figure 24 shows the results showing the gene expression inhibition activity of osteoclast differentiation inducing factors in a collagen-induced arthritis mouse model of a chaperonin protein derived from the Propionibacterium freudencii MJ2 strain of the present invention.
[0045] Figure 25 shows the results of confirming the osteoclast differentiation inhibition activity of the chaperonin protein derived from the Propionibacterium freudencii MJ2 strain of the present invention in a collagen-induced arthritis mouse model.
[0046] The present invention was conducted while researching to develop a new therapeutic agent that can effectively improve or treat rheumatoid arthritis, and for the first time, the inventors have discovered that extracellular vesicles or 60 kDa chaperonin protein (Cpn60) derived from the Propionibacterium freudencii MJ2 strain, which was isolated and identified from crude oil, have the activity of effectively preventing, improving or treating rheumatoid arthritis.
[0047] Accordingly, the present invention is characterized by providing a pharmaceutical composition for preventing or treating rheumatoid arthritis, which contains extracellular vesicles or 60 kDa chaperonin protein (Cpn60) derived from a strain of Propionibacterium freudenreichii as an active ingredient.
[0048] Specifically, the Propionibacterium freudenreichii strain may be a Propionibacterium freudenreichiiMJ2 (accession number KCCM12272P) strain.
[0049] According to the present invention, the Propionibacterium freudenreichii MJ2 strain was first isolated by the inventors of the present invention by confirming the presence of P. freudenreichii in raw milk procured from Gimpo Ranch, Gyeonggi-do, by NGS (next generation sequencing) method, culturing the milk for 7 days at 30℃ under anaerobic conditions using YELA medium, and then isolating a single colony to select a candidate strain, and using 16s rDNA sequencing (universal primer: 1492R), the inventors of the present invention deposited the strain at the Korea Center for Microorganism Conservation on June 8, 2018, and was assigned the accession number KCCM 12272P.
[0050] In order to identify a pharmacologically effective ingredient having a rheumatoid arthritis treatment effect against the Propionibacterium freudencii MJ2 strain, the present inventors analyzed the degree of osteoclast differentiation inhibition using the strain itself (live cells, dead cells), a culture of the strain (a culture containing the strain), a culture medium of the strain (a culture medium from which the strain has been removed), and extracellular vesicles isolated from the culture medium of the strain.
[0051] As a result, it was found that the osteoclast differentiation inhibition effect of the extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain itself (live cells, dead cells) was significantly superior, and this effect was also superior to that of the culture of the strain (culture containing the strain) and the culture solution of the strain (culture solution from which the strain was removed).
[0052] Accordingly, the inventors of the present invention conducted the following experiments to determine whether extracellular vesicles isolated from Propionibacterium freudencii MJ2 strain can improve, prevent, or treat rheumatoid arthritis.
[0053] In one embodiment of the present invention, Propionibacterium freudencii MJ2 strain was cultured at 30°C for 48 hours, and then the culture solution was centrifuged at 4°C for 20 minutes at a speed of 10,000×g to obtain only the supernatant. Then, extracellular vesicles of 100 kDa or more were separated using a filter paper, and then this was centrifuged again at 4°C for 3 hours at a speed of 150,000×g to obtain extracellular vesicles isolated from the strain.
[0054] Afterwards, the characteristics of the extracellular vesicles obtained by the above method were analyzed, and the size of the separated extracellular vesicles of the present invention was found to be about 150 to 200 nm in particle diameter, preferably about 170 nm, and it was confirmed that they had a spherical shape.
[0055] In another embodiment of the present invention, as a result of confirming the proteins contained in the separated extracellular vesicles through proteome analysis, it was confirmed that 20 types of proteins shown in Table 1 below, including 60 kDa chaperonin, Chain A, and Methylmalonyl-CoA carboxyltransferase 12S subunit protein, were predominant, and in particular, whether the 60 kDa chaperonin protein had the activity of preventing, improving, and treating rheumatoid arthritis was confirmed.
[0056] First, in order to confirm whether the extracellular vesicles isolated from Propionibacterium freudencii MJ2 strain have an inhibitory effect on osteoclast differentiation, the inventors treated a macrophage cell line with RANKL (Receptor activator of nuclear factor kappa-β ligand) to induce osteoclast differentiation, and then additionally treated the extracellular vesicles of the present invention at various concentrations, and then analyzed the expression level of osteoclast differentiation markers and the number of TRAP-activated osteoclasts. As a result, 1 × 10 6 particles / mL to 1 × 10 8 The groups treated with extracellular vesicles at 1 × 10 particles / mL showed inhibition of osteoclast differentiation compared to the control group that was not treated with extracellular vesicles. Meanwhile, 9 In the group treated with extracellular vesicles at particles / mL, cell death was observed.
[0057] In another embodiment of the present invention, after administering extracellular vesicles isolated from Propionibacterium freudencii MJ2 strain to collagen-induced rheumatoid arthritis mice (extracellular vesicles were 1 × 10 7 particles / mL and 1 × 10 8particles / mL), and whether the disease was improved was observed. As a result, it was confirmed that the symptoms of rheumatoid arthritis were improved in the group administered the extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain of the present invention, even through visual observation, and it was confirmed that there was an effect of alleviating bone erosion and damage to the knee joint. In addition, it was confirmed that the concentrations of collagen antigen-specific total IgG, IgG1, and IgG2a antibodies, which were promoted in the blood when rheumatoid arthritis was induced, were significantly reduced.
[0058] Therefore, through these results, the inventors of the present invention confirmed that the extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain have the effect of preventing, improving, and treating rheumatoid arthritis, and the treatment amount of the extracellular vesicles of the present invention for this effect is 1 × 10 6 particles / mL to 1 × 10 8 It was found that particles / mL was desirable.
[0059] In addition, in another embodiment of the present invention, a 60 kDa chaperonin protein (Cpn60), which is a major protein identified in extracellular endoplasmic reticulum, was synthesized, and the osteoclast differentiation inhibitory activity of the 60 kDa chaperonin protein (Cpn60) was analyzed, and it was confirmed that the 60 kDa chaperonin protein (Cpn60) also has an effect of inhibiting osteoclast differentiation.
[0060] The above 60 kDa chaperonin protein is a protein conserved in the evolutionary stage that is essential for eukaryotic and prokaryotic cells, and in addition to its unique protein folding function, it is known to act as a receptor that binds to ligands inside and outside the cell and as a cell-to-cell signaling substance. However, there has been no research yet on whether the 60 kDa chaperonin protein can prevent, improve, and treat rheumatoid arthritis.
[0061] Furthermore, in order to confirm whether the extracellular vesicles and 60 kDa chaperonin protein isolated from the Propionibacterium freudencii MJ2 strain have pharmacological efficacy capable of actually treating rheumatoid arthritis, the inventors administered collagen to mice to which the extracellular vesicles and 60 kDa chaperonin protein of the present invention were respectively administered, thereby inducing rheumatoid arthritis, and then analyzed the arthritis disease index of each mouse.
[0062] As a result, mice in which rheumatoid arthritis was induced without administration of extracellular vesicles or 60 kDa chaperonin protein showed an increase in arthritis disease index over time and a worsening of symptoms, whereas in the group administered the extracellular vesicles or 60 kDa chaperonin protein of the present invention, the arthritis disease index was significantly reduced and the symptoms of rheumatoid arthritis were alleviated.
[0063] Through these results, the inventors of the present invention were able to find that the extracellular vesicles or 60 kDa chaperonin protein of the present invention can prevent and improve rheumatoid arthritis.
[0064] In another embodiment, an experiment was conducted to determine whether the extracellular vesicles or 60 kDa chaperonin protein of the present invention could alleviate bone erosion, a symptom that occurs when rheumatoid arthritis develops, i.e., cells causing inflammation eat away at the bone surface, causing the bone to melt or become deeply pitted.
[0065] As a result, it was confirmed that the bone erosion area was significantly reduced in the group of mice administered the extracellular vesicles or 60 kDa chaperonin protein of the present invention compared to the control group that was not administered the same, and that joint knee damage was also alleviated.
[0066] In addition, the inventors of the present invention measured the amount of collagen antigen-specific IgG in plasma to serologically confirm the degree of symptoms of rheumatoid arthritis, an autoimmune disease. As a result, it was found that the production of collagen antigen-specific IgG antibodies was increased in the plasma of control mice induced with rheumatoid arthritis, whereas in the group of mice administered the extracellular vesicles or 60 kDa chaperonin protein of the present invention, the concentrations of total IgG, IgG1, and IgG2a antibodies were significantly reduced compared to the disease control group.
[0067] In addition, in the group of mice administered the extracellular vesicles or 60 kDa chaperonin protein of the present invention, the level of production of inflammatory cytokines was significantly reduced compared to the disease control group, while the expression of IL-10, an anti-inflammatory cytokine, was increased.
[0068] These results indicate that the extracellular vesicles or 60 kDa chaperonin protein of the present invention can suppress excessive immune responses and excessive inflammatory responses, and that rheumatoid arthritis can be prevented, improved, and treated through control of immune responses and inflammatory responses.
[0069] Therefore, the present invention can provide a pharmaceutical composition for preventing or treating rheumatoid arthritis, which contains extracellular vesicles or 60 kDa chaperonin protein (Cpn60) derived from a strain of Propionibacterium freudenreichii as an active ingredient.
[0070] The pharmaceutical composition according to the present invention may include a pharmaceutically acceptable carrier in addition to the active ingredient. At this time, the pharmaceutically acceptable carrier is one commonly used in formulations, and includes, but is not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition to the above ingredients, the composition may further include a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.
[0071] The pharmaceutical composition of the present invention can be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically) depending on the intended method, and the dosage varies depending on the patient's condition and weight, the degree of disease, the drug form, the route of administration, and the time, but can be appropriately selected by those skilled in the art.
[0072] In the present invention, “prevention” means any act of suppressing or delaying the onset of rheumatoid arthritis by administering a pharmaceutical composition according to the present invention.
[0073] In the present invention, “treatment” means any act in which the symptoms of rheumatoid arthritis are improved or beneficially changed by administering a pharmaceutical composition according to the present invention.
[0074] In the present invention, “improvement” means any action that reduces a parameter related to rheumatoid arthritis, for example, the severity of symptoms, by administering a composition according to the present invention.
[0075] The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment. The effective dosage level may be determined based on the type and severity of the patient's disease, the activity and sensitivity of the drug, the time of administration, the route of administration and excretion rate, the duration of treatment, concurrently used drugs, and other factors well known in the medical field.
[0076] The pharmaceutical compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents. They may be administered sequentially or simultaneously with conventional therapeutic agents, or in single or multiple doses. Taking all of the above factors into account, it is important to administer an amount that achieves maximum efficacy with the minimum amount possible without causing adverse effects. This can be readily determined by those skilled in the art.
[0077] Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the patient's age, sex, condition, weight, absorption rate, inactivation rate and excretion rate of the active ingredient in the body, type of disease, and concomitantly administered drugs, and is generally 0.001 to 150 mg per 1 kg of body weight, preferably 0.01 to 100 mg, administered daily or every other day, or divided into 1 to 3 times a day. However, since the dosage may increase or decrease depending on the route of administration, severity of rheumatoid arthritis, sex, weight, age, etc., the above dosage does not limit the scope of the present invention in any way.
[0078] In another aspect of the present invention, the present invention provides a method for preventing, controlling or treating rheumatoid arthritis, comprising administering the pharmaceutical composition to a subject.
[0079] In the present invention, the term "subject" means a subject requiring a method for preventing, controlling or treating a disease, and more specifically, means a mammal such as a human or non-human primate, mouse, rat, dog, cat, horse and cow.
[0080] In addition, the present invention can provide a food composition for preventing or improving rheumatoid arthritis, which contains extracellular vesicles or 60 kDa chaperonin protein (Cpn60) derived from a strain of Propionibacterium freudenreichii as an active ingredient.
[0081] More specifically, the composition of the present invention can be added to a health functional food for the purpose of preventing or improving rheumatoid arthritis, and when the composition of the present invention is used as a food additive, the composition can be added as is or used together with other foods or food ingredients, and can be used appropriately according to a conventional method. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment). Generally, when manufacturing a food or beverage, the composition of the present invention is added in an amount of 15 wt% or less, preferably 10 wt% or less, based on the raw material. However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount can be below the above range, and since there is no problem in terms of safety, the active ingredient can also be used in an amount above the above range.
[0082] There are no specific restrictions on the types of the above foods. Examples of foods to which the above substances can be added include meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and all health functional foods in the conventional sense are included.
[0083] The health beverage composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients, like conventional beverages. The natural carbohydrates mentioned above are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, natural sweeteners such as thaumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame can be used. The proportion of the natural carbohydrate is generally about 0.01 to 0.20 g, and preferably about 0.04 to 0.10 g, per 100 ml of the composition of the present invention.
[0084] In addition to the above, the composition of the present invention may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the composition of the present invention may contain fruit pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks. These ingredients may be used independently or in combination. The proportion of these additives is not particularly critical, but is typically selected within the range of 0.01 to 0.20 parts by weight per 100 parts by weight of the composition of the present invention.
[0085] In addition, as confirmed in one embodiment of the present invention, the extracellular vesicles or 60 kDa chaperonin protein (Cpn60) derived from the Propionibacterium freudencii MJ2 strain of the present invention has an effect of inhibiting the production of inflammatory cytokines, and thus, when utilized, it can be used as a cosmetic composition having anti-inflammatory activity.
[0086] Accordingly, the present invention can provide an anti-inflammatory cosmetic composition comprising extracellular vesicles or 60 kDa chaperonin protein (Cpn60) derived from the Propionibacterium freudencii MJ2 strain as an effective ingredient.
[0087] The components included in the cosmetic composition of the present invention may include, in addition to the extracellular vesicles or 60 kDa chaperonin protein (Cpn60) derived from the Propionibacterium freudencii MJ2 strain as an active ingredient, components commonly used in cosmetic compositions, such as conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances, and carriers.
[0088] The cosmetic composition of the present invention can be manufactured into any formulation commonly manufactured in the art, and for example, can be formulated into a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, and spray, but is not limited thereto. More specifically, the cosmetic composition of the present invention can be manufactured into a formulation of a flexible toner, a nourishing toner, a nourishing cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray, or a powder.
[0089] When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component. When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizer or an emulsifier may be used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan. When the formulation of the present invention is a suspension, liquid diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth may be used as carrier components. When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as carrier components, and particularly in the case of a spray, a propellant such as chlorofluorohydrocarbon, propane / butane or dimethyl ether may be additionally included. When the formulation of the present invention is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester may be used as a carrier component.
[0090] The present invention will be described in more detail through the following examples. These examples are intended to illustrate the present invention more specifically, and the scope of the present invention is not limited to these examples.
[0091]
[0092] <Example 1>
[0093] Isolation of extracellular vesicles from Propionibacterium freudencii MJ2 strain
[0094] The Propionibacterium freudenreichiiMJ2 strain used in the present invention is a strain that the inventor deposited on June 8, 2018, at the Korea Microbiological Conservation Center and was assigned the deposit number KCCM12272P. P. freudenreichiiMJ2 is a strain that was selected as a candidate strain through a process of isolating a single colony using a selective medium (YELA) from raw milk from Gimpo Ranch, Gyeonggi-do, and then identified using 16s rDNA sequencing.
[0095] To isolate extracellular vesicles from Propionibacterium freudenreichii MJ2 strain, the inventors inoculated MJ2 strains activated at least twice into YELA medium, created an anaerobic environment using GasPak (BD, Franklin Lakes, NJ, USA), and cultured at 30°C for 48 hours. The cultured bacterial solution was centrifuged at 10,000×g for 20 minutes at 4°C, and only the supernatant was filtered through a 0.22 μm vacuum filter. Thereafter, extracellular vesicles of 100 kDa or larger were isolated by ultrafiltration (Amicon® Stirred Ultrafiltration Cell, Millipore, USA) with a filter having a MWCO (molecular weight cutoff) of 100 kDa. After separation and concentration, the solution was filtered again through a 0.22 μm vacuum filter to remove waste and cell debris, and the obtained solution was ultracentrifuged at 150,000×g for 3 hours at 4°C (ultracentrifugation, CP100WX, Hitachi, Tokyo, Japan) to isolate extracellular vesicles. In addition, the pellet was resuspended in physiological saline (PBS, phosphate-buffered saline) and then ultracentrifuged again at 150,000×g for 3 hours at 4°C to remove medium components, thereby obtaining extracellular vesicles from the Propionibacterium freudenreichiiMJ2 strain.
[0096]
[0097] <Example 2>
[0098] Identification of extracellular vesicles derived from Propionibacterium freudencii strain MJ2
[0099] In order to confirm the extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain in the above <Example 1>, the size and shape were analyzed using nanoparticle tracking analysis (NTA), scanning electron microscope (SEM), and transmission electron microscope (TEM).
[0100]
[0101] As a result, as shown in FIGS. 1 to 3, the size of the extracellular vesicles isolated in the present invention was confirmed to be about 170 nm and it was found that they had a spherical shape.
[0102]
[0103] <Example 3>
[0104] Identification of proteins in extracellular vesicles derived from Propionibacterium freudencii strain MJ2.
[0105] The present inventors used an in-solution trypsin protein digestion method for proteome analysis of extracellular vesicles derived from the Propionibacterium freudenreichii MJ2 strain isolated in the present invention. Specifically, 100 μg of extracellular vesicles isolated from the Propionibacterium freudenreichii MJ2 strain in <Example 1> was dissolved in a digestion solution containing 8 M urea (Sigma, St. Louis, MO, USA) and 1% protease inhibitor (Thermo Scientific, Waltham, MA, USA), and then 8 M urea and 25 mM DTT (Sigma, St. Louis, MO, USA) were added, and denaturation and reduction reactions were performed at 60°C for 45 minutes. After cooling, the sample was added with 25 mM iodoacetamide solution dissolved in 25 mM ammonium bicarbonate and reacted for 1 hour at room temperature in a light-protected state. Urea was diluted to a concentration of 1 M with 25 mM ammonium bicarbonate, and the 8-fold diluted protein was digested overnight at 37°C using Pierce trypsin protease (MS grade, Thermo Scientific, Waltham, MA, USA). The sample after the reaction was C 18 Salt was removed using a column (Oasis® HLB 1 cc Vac cartridges, Waters Corporation, MA, USA), and nano-mass analysis (Nano-LC-MS / MS) was performed using Easy n-LC (Thermo Fisher San Jose, CA, USA) and LTQ Orbitrap XL mass spectrometer (Thermo Fisher, San Jose, CA, USA). The degraded peptides of extracellular vesicles derived from the MJ2 strain obtained by the in-solution digestion method were separated using a 3 μm pore size C18 After loading onto a nanobore column (150 mm × 0.1 mm), proteins were separated under the following conditions: 0-40% buffer B for 80 min, 40-60% buffer B for 4 min, 95% buffer B for 4 min, 100% buffer A for 6 min; flow rate 500 nl / min (buffer A composition: 0.1% formic acid, 3% acetonitrile in H2O, buffer B composition: 0.1% formic acid in acetonitrile).
[0106] Additionally, mass spectra were acquired using data-dependent acquisition with 10 MS / MS scans after a full mass scan (350-1200 m / z), and the analysis of proteins present in extracellular vesicles derived from the MJ2 strain was performed using the Mascot algorithm (Matrixscience, USA) to identify peptide sequences present in the protein sequence database.
[0107] As a result of proteome analysis of extracellular vesicles using the above method, 20 proteins listed in Table 1 below were identified, and it was found that 60 kDa chaperonin, Chain A, and Methylmalonyl-CoA carboxyltransferase 12S subunit proteins were the main proteins.
[0108] 세포외 소포체에 대한 프로테옴 분석AccessionProtein descriptionProtein scoreMonoisotopic mass (Mr)pICEH03981.160 kDa chaperonin 1 (Protein Cpn60 1) (groEL protein 1) (Heat shock protein 60 1)362562444.70pdb|1ON3|AChain A, Methylmalonyl-CoA carboxyltransferase 12S subunit3343345.38AAA25676.1methylmalonyl-CoA carboxyltransferase subunit 12S monomer289660575.22pdb|1RR2|AChain A, transcarboxylase 5S subunit164526235.64CEH00767.1penicillin-binding protein (peptidoglycan glycosyltransferase)130753827.71CEH00696.1iron-sulfur protein107577766.75CEH01375.1dolichyl-phosphate beta-D-mannosyltransferase86321235.34CEH02479.1surface layer protein A (S-layer protein A)78585524.69CEH00694.1Hypothetical protein PFCIRM127_1214577232274.70CEH00758.1Carboxylic ester hydrolase74467245.38CEH00733.1Methylmalonyl-CoA carboxytransferase, 1.3S subunit (Transcarboxylase, 1.3S subunit). 123bp73123605.39CEH02032.1Enolase 166460054.47CEH02295.150S ribosomal protein L2573040811.08CEH04045.1Hypothetical protein PFCIRM125_1127544107396.59CEH00999.1dihydrolipoyllysine-residue (2-methylpropanoyl)transferase. Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex (E2) (Dihydrolipoamide branched chain transacylase)42483575.58CEH00698.1Oxidoreductase39294765.56CEH00239.1Putative minor extracellular serine protease391503615.25CEH01003.12-oxoisovalerate dehydrogenase subunit alpha (Branched-chain alpha-keto acid dehydrogenase E1 component alpha chain) (BCKDH E1-alpha)38406474.60CEH02678.1Hypothetical protein PFCIRM125_0673535359105.29CEH01770.1polar amino acid ABC transporter, binding protein component33316724.84.
[0109]
[0110] <Example 4>
[0111] Analysis of cytotoxicity following treatment with extracellular vesicles derived from Propionibacterium freudencii MJ2 strain.
[0112] To determine whether the extracellular vesicles derived from Propionibacterium freudenreichiiMJ2 according to the present invention are cytotoxic, Raw 264.7 cells were seeded at 1 × 10 in a 96-well plate. 4After dividing the cells into 1 × 10 cells / mL, they were cultured in a 5% CO2 incubator at 37°C for 24 hours. After 24 hours, the extracellular vesicles of the present invention, diluted with DMEM (Dulbecco's Modified Eagle Medium) serum-free medium, were added to Raw 264.7 cells at a density of 1 × 10 6 , 1 × 10 7 , 1 × 10 8 , 1 × 10 9 Each cell was treated with 100 particles / mL and cultured for 4 days. Afterwards, cell viability was measured using a SpectraMax 340PC384 microplate reader (Molecular Devices, Sunnyvale, CA, USA) using MTT reagent.
[0113]
[0114] As a result, as shown in Fig. 4, compared to the control group cultured in DMEM medium that did not treat the extracellular vesicles of the present invention, the extracellular vesicles were 1 × 10 6 ~ 1 × 10 8 As the experimental group treated with particles / mL showed a cell survival rate of over 90%, the inventors of the present invention were able to determine that the extracellular cell bodies isolated from the MJ2 strain of the present invention do not cause toxicity to cells.
[0115]
[0116] <Example 5>
[0117] Analysis of the osteoclast differentiation inhibition ability of extracellular vesicles derived from Propionibacterium freudencii MJ2 strain.
[0118] The present inventors performed the following experiment to confirm whether the extracellular vesicles derived from the Propionibacterium freudencii MJ2 strain isolated in the above <Example 1> have osteoclast differentiation inhibitory activity.
[0119]
[0120] <5-1> Inhibition of the number of osteoclasts activated by TRAP (Tartrate-resistant acid phosphatase)
[0121] Raw 264.7 cells, a macrophage cell line, were cultured in DMEM (Dulbecco's Modified Eagle Medium) medium. The medium was supplemented with 10% FBS, 100 units / mL penicillin, and 100 μg / mL streptomycin, and cultured at 37°C in a 5% CO2-95% atmosphere. When the cells reached 80% confluence, they were removed from the culture plate using a scraper, and 1 × 10 4 After adjusting the cell count to 10 cells / mL and stabilizing in a 37°C incubator for one day, the medium was replaced with α-MEM (Minimum Essential Medium Eagle-Alpha Modification) medium supplemented with 10% FBS, 100 units / mL penicillin, and 100 μg / mL streptomycin. The replaced medium was treated with a diluted 50 ng / mL RANKL (Receptor activator of nuclear factor kappa-β ligand) to induce differentiation of the macrophages into osteoclasts. Afterwards, 1 × 10 extracellular vesicles according to the present invention were added. 6 , 1 × 10 7 , 1 × 10 8 Each was further treated with particles / mL and then cultured for 4 days.
[0122] Afterwards, the number of differentiated osteoclasts was measured using TRAP staining to confirm the activity of TRAP (Tartrate-resistant acid phosphatase), a marker of osteoclasts, in each experimental cell group. To this end, the supernatant of the cells that underwent the process was removed, the cells were washed with PBS, and then fixed. The fixed cells were stained using a TRACP & ALP Assay Kit (Takara, Shiga, Japan) at 37°C for 30 minutes. The supernatant was removed, the cells were washed with distilled water, and osteoclasts with three or more nuclei, i.e., differentiated osteoclasts, were observed under a light microscope.
[0123]
[0124] As a result, as shown in Fig. 5, in the group treated with the extracellular vesicles of the present invention, the number of TRAP-activated osteoclasts was significantly reduced compared to the control group treated with only RANKL and not treated with the extracellular vesicles.
[0125] Through these results, the inventors were able to find that extracellular vesicles derived from Propionibacterium freudencii MJ2 strain have the activity of inhibiting osteoclast differentiation.
[0126]
[0127] <5-2> Inhibition of gene expression of osteoclast differentiation inducing factors
[0128] The supernatant was removed from the cultured cells in the same manner as in Example <5-1>, and RNA was isolated from each cell experimental group using Ribo-Ex (GeneAll Biotechnology, Seoul, Korea). The isolated RNA was synthesized into cDNA using the Revert Aid First Strand cDNA kit (Thermo Scientific, Waltham, MA, USA), and real-time PCR was performed using a QuantStudio 6 Flex (Life Technologies, Thermo Scientific) instrument with KAPA SYBR FAST qPCR kit (Kapa Biosystems, Foster City, CA, USA) reagents. The information on the primers used is as described in Table 2 below.
[0129] Primer information for each gene used in real-time PCRGeneForward (5′-3′)Reverse (5′-3′)GAPDHACCCAGAAGACTGTGGATGGCACATTGGGGGTAGGAACACRANKTGCAGCTCAACAAGGATACGGAGCTGCAGACCACATCTGANFκBTCCTGGCCTCTAGCCTTGTAGCCAAGGAAGAAAAGTGCTGc-fosCCAGTCAAGAGCATCAGCAAAAGTAGTGCAGCCCGGAGTANFATc1GGTGCTGTCTGGCCATAACTGCGGAAAGGTGGTATCTCAACalcrCGGACTTTGACACAGCAGAAGTCACCCTCTGGCAGCTAAGCtskCAGCTTCCCCAAGATGTGATAGCACCAACGAGAGGAGAAAAtp6v0d2GACCCTGTGGCACTTTTTGTGCTTGCATTTGGGGAATCTA
[0130] As a result, as shown in Fig. 6, the extracellular vesicles of the present invention were 1 × 10 7 particles / mL and 1 × 10 8The group treated with particles / mL showed a significant decrease in the expression of genes involved in promoting osteoclast differentiation compared to the control group treated with only RANKL.
[0131]
[0132] <5-3> Inhibition of protein expression of osteoclast differentiation inducing factors
[0133] In the above Example <5-2>, the cells used in the experiment were centrifuged at 2,500×g at 4℃ for 5 minutes to remove the supernatant and obtain the cells. The cells were washed with Cold-PBS (physiological saline) and lysed using RIPA lysis buffer (BYLABS, Korea) and 1% protease inhibitor cocktail (Thermo Scientific) by placing the cells on ice for 15 minutes. The lysed cells were centrifuged at 14,000×g at 4℃ for 15 minutes, and the supernatant was used as a protein sample. The protein amount was quantified using the Pierce BCA Protein Assay kit (Thermo Scientific), and after denaturation at 100℃, Western blotting was performed. 10 μg of protein was loaded onto a 10% SDS-polyacrylamide gel, separated by SDS-PAGE, transferred to a PVDF membrane, reacted with a specific antibody, and protein bands were confirmed using UVP ChemStudio (Analytik, Jena, Germany).
[0134] As a result, as shown in Fig. 7, the control group in which rheumatoid arthritis was induced by promoting osteoclast differentiation through RANKL treatment showed a significantly higher expression level of c-fos, RANK, and NFATc1 compared to the group in which rheumatoid arthritis was not induced without RANKL treatment, whereas the experimental groups administered the extracellular vesicles of the present invention showed a significant decrease in the expression level of c-fos, RANK, and NFATc1 in a concentration-dependent manner compared to the group that was not administered the extracellular vesicles.
[0135] Through these results, the inventors of the present invention were able to determine that the extracellular vesicles derived from the Propionibacterium freudencii MJ2 strain according to the present invention can not only suppress the expression of genes that induce osteoclast differentiation, which is a major cause of rheumatoid arthritis, but also suppress the expression of proteins involved in osteoclast differentiation, thereby preventing, improving, and treating the onset of rheumatoid arthritis caused by osteoclast differentiation.
[0136]
[0137] <Example 6>
[0138] Confirmation of the improvement effect of rheumatoid arthritis following administration of extracellular vesicles derived from Propionibacterium freudencii MJ2 strain.
[0139]
[0140] <6-1> Production of collagen-induced rheumatoid arthritis (CIA) mice
[0141] Eight-week-old male DBA / 1J mice (Central Laboratory Animal, Seoul, Korea) were used as a mouse model of collagen-induced rheumatoid arthritis. After one week of adaptation, they were randomly divided into eight groups. The group was administered PBS without inducing arthritis (Control), the group was administered PBS after inducing arthritis (Model), and the group was administered 1 × 10 low-concentration P. freudentreichii MJ2-derived extracellular vesicles after inducing arthritis (Model). 7 The group administered particles / mouse (Low-dose Extracellular Vesicles; LDEV) and high concentration of 1 × 10 P. freudentreichii MJ2-derived extracellular vesicles after inducing arthritis. 8The mice were divided into groups administered with particles / mouse (High-dose Extracellular Vesicles; HDEV). Arthritis was induced by intradermal injection of type II bovine collagen (2 mg / mL) emulsified 1:1 with complete Freund's Adjuvant (CFA, 1 mg / mL) into the tail for the first immunization. Three weeks later, the mice were injected intradermally with type II bovine collagen (2 mg / mL) emulsified 1:1 with incomplete Freund's Adjuvant (IFA) into the tail for the second boost. After arthritis was induced, the severity of swelling and inflammation was visually evaluated according to the Arthritic score criteria (Table 3) and given a score.
[0142] Arthritis score criteria: 0 points: No symptoms of arthritis such as swelling, redness, or swelling observed. 1 point: Redness with two or more swellings, or mild swelling and redness. 2 points: Clear redness, swelling, or swelling in two or more places. 3 points: Significant swelling and swelling from the toes to the entire ankle, and freedom of movement is not possible.
[0143] As a result, as shown in Fig. 8, the group that induced arthritis by administering PBS showed the most severe arthritis symptoms, and the group that induced arthritis by administering extracellular vesicles derived from the P. freudenreichiiMJ2 strain showed a significant improvement in arthritis symptoms visually.
[0144]
[0145] <6-2> Analysis of hepatotoxicity markers in collagen-induced rheumatoid arthritis (CIA) mice
[0146] As shown in Figure 9, the serum levels of AST (aspartate aminotransferase) and ALT (alanine aminotransferase), indicators of hepatotoxicity, did not show any significant differences between the experimental groups. Therefore, these results indicate that the extracellular vesicles used in the present invention do not cause hepatotoxicity in mice within the concentration range.
[0147]
[0148] <6-3> Analysis of the effect of administration of extracellular vesicles according to the present invention on bone erosion in a mouse model of rheumatoid arthritis
[0149] As a result of performing H&E staining analysis to compare bone erosion and damage of the knee joint, it was found that damage to the knee joint was reduced by administration of the extracellular vesicle of the present invention, and it was found that bone erosion and knee joint damage could be alleviated when the extracellular vesicle was administered to rheumatoid arthritis mice (Fig. 10).
[0150]
[0151] <6-4> Analysis of collagen antigen-specific igG, IgG1, and IgG2a antibody concentrations following administration of the extracellular vesicles of the present invention in mice induced with collagen-induced rheumatoid arthritis
[0152] Blood from the mouse used in the above Example <6-1> was collected, plasma was separated, and the concentration of collagen antigen-specific IgG, IgG1, and IgG2a antibodies was measured using the ELISA method.
[0153] As a result, as shown in Fig. 11, it was confirmed that the production of collagen antigen-specific IgG antibodies in the blood was promoted when arthritis was induced, whereas in the group administered the extracellular vesicles of the present invention, the concentrations of collagen antigen-specific total IgG, IgG1, and IgG2a antibodies were found to be significantly reduced.
[0154]
[0155] <6-5> Analysis of changes in immune response and inflammatory cytokines following administration of the extracellular vesicles of the present invention in mice induced with collagen-induced rheumatoid arthritis
[0156] Blood was collected from the mice used in the above Example <6-1>, and the serum was used to analyze the levels of inflammatory cytokines TNFα and IL-6 for each group using the ELISA method, and the mRNA expression level of IL-17 was analyzed using the quantitative real-time PCR method. In addition, the amount of IL-10, an anti-inflammatory cytokine, was measured using the ELISA method.
[0157] As a result, as shown in Fig. 12, the levels of inflammatory cytokines TNFα, IL-6, and IL-17 were significantly reduced in the group administered the high-concentration extracellular vesicles of the present invention compared to the rheumatoid arthritis-induced group. IL-10 tended to increase in the group administered the high-concentration extracellular vesicles of the present invention.
[0158] Therefore, through these results, the inventors of the present invention were able to find out that administration of the extracellular vesicles of the present invention can suppress excessive immune response caused by rheumatoid arthritis, suppress the level of inflammatory cytokines, and increase the level of anti-inflammatory cytokines.
[0159]
[0160] <6-6> Analysis of the effect of extracellular vesicle administration on osteoclast differentiation in mice induced with collagen-induced rheumatoid arthritis
[0161] Synovial tissue was isolated from the mouse used in the above Example <6-1>, and the relative mRNA expression levels of factors related to osteoclast differentiation, including Nuclear factor of activated T cells 1 (NFATc1), Cathepsin K (Ctsk), Calcitonin receptor (Calcr), Matrix metallopeptidase 9 (MMP9), Osteoprotegrin (OPG), and Receptor activator of nuclear factor-κB ligand (RANKL), within the tissue were analyzed using quantitative real-time PCR.
[0162] As a result, as shown in Fig. 13, the expression levels of NFATc1, Ctsk, Calcr, and MMP9 were significantly increased in the group that induced rheumatoid arthritis compared to the group that did not induce rheumatoid arthritis, whereas in the group administered the extracellular vesicles of the present invention, the expression levels of NFATc1 and MMP9 were significantly decreased at all concentrations, and the expression levels of Ctsk and Calcr were significantly decreased at high concentrations. In addition, the expression ratio of Osteoprotegrin (OPG) / RANKL, which inhibits the differentiation of osteoclasts and promotes the differentiation of osteoblasts, was significantly increased in the group administered a high concentration of P. freudenreichiiMJ2 strain-derived extracellular vesicles.
[0163] In addition, when the number of TRAP-positive cells (osteoclasts) appearing in red by TRAP staining of knee joint tissue was analyzed, the number of TRAP-positive cells was found to be significantly increased in the rheumatoid arthritis-induced group compared to the group not induced with rheumatoid arthritis. Meanwhile, the group administered with the extracellular vesicles of the present invention showed a significant decrease in the number of TRAP-positive cells compared to the rheumatoid arthritis-induced group (see Fig. 14).
[0164] Through these results, the inventors of the present invention were able to find that the extracellular vesicles isolated from the Propionibacterium freudencii MJ2 strain of the present invention can effectively inhibit the differentiation of osteoclasts and improve inflammatory responses, thereby preventing, improving, and treating rheumatoid arthritis.
[0165]
[0166] <Example 7>
[0167] Preparation of a 60 kDa chaperonin protein (Cpn60) contained in extracellular vesicles derived from Propionibacterium freudencii MJ2 strain
[0168] In the above <Example 3>, the inventors of the present invention identified major proteins contained in extracellular vesicles isolated from Propionibacterium freudencii MJ2 strain through proteome analysis, and confirmed in Table 1 that a 60 kDa chaperonin protein (Cpn60) was contained as a major factor in the extracellular vesicles. Accordingly, the inventors of the present invention synthesized the 60 kDa chaperonin protein (Cpn60) using an ExiProgen™ EC Protein Synthesis Kit and ExiProgen™ equipment (Bioneer, Daejeon, Korea) known in the art, and isolated and purified the synthesized Cpn60 protein.
[0169]
[0170] As a result, the purified Cpn60 protein synthesized above was confirmed through SDS-PAGE and Coomassie blue staining, and as shown in Fig. 15, the purified Cpn60 protein at around 60 kDa was confirmed through the above process.
[0171]
[0172] <Example 8>
[0173] Analysis of the cytotoxicity of the 60 kDa chaperonin protein (Cpn60) derived from Propionibacterium freudencii MJ2 strain.
[0174] The cytotoxicity of the 60 kDa chaperonin protein (Cpn60) purified in the above <Example 7> was analyzed. To this end, Raw 264.7 cells were treated with 50 ng / ml of RANKL to induce differentiation into osteoclasts, and Cpn60 protein was treated at concentrations of 1.25 to 5 μg / ml, and the cytotoxicity was analyzed using the MTT method.
[0175]
[0176] As a result, as shown in Fig. 16, it was confirmed that no cytotoxicity was observed within all treatment concentration ranges in which the 60 kDa chaperonin protein (Cpn60) of the present invention was treated.
[0177]
[0178] <Example 9>
[0179] Inhibition of TARP enzyme activity by a 60 kDa chaperonin protein (Cpn60) derived from Propionibacterium freudencii MJ2 strain
[0180] Raw 264.7 cells were treated with 50 ng / ml of RANKL to induce differentiation into osteoclasts, and then treated with Cpn60 protein for 4 days. The cells were then stained for TRAP enzyme, an osteoclast differentiation marker, and observed.
[0181]
[0182] As a result, as shown in Figure 17, it was confirmed that the group treated with Cpn60 protein had a significant decrease in the activity of TRAP enzyme, a differentiation marker of osteoclasts.
[0183]
[0184] <Example 10>
[0185] Analysis of the inhibitory effect of the 60 kDa chaperonin protein (Cpn60) derived from Propionibacterium freudencii MJ2 strain on the expression of genes related to osteoclast differentiation.
[0186] Raw 264.7 cells were treated with 50 ng / ml of RANKL to induce differentiation into osteoclasts, and then treated with Cpn60 for 3 days. RNA was extracted from the cells of each experimental group, and the changes in the expression levels of genes related to osteoclast differentiation were analyzed using real-time PCR.
[0187]
[0188] As a result, as shown in Figure 18, the group treated with Cpn60 protein showed a significant decrease in the expression levels of genes related to osteoclast differentiation, RANK, NFκB, c-fos, NFATc1, Calcr, Ctsk, and Atp6v0d2, compared to the group treated with only RANKL.
[0189]
[0190] <Example 11>
[0191] Confirmation of the improvement effect of rheumatoid arthritis following administration of a 60 kDa chaperonin protein derived from the Propionibacterium freudencii MJ2 strain.
[0192]
[0193] <11-1> Production of collagen-induced rheumatoid arthritis (CIA) mice
[0194] Eight-week-old male DBA / 1J mice (Central Laboratory Animal, Seoul, Korea) were used as a collagen-induced rheumatoid arthritis mouse model. After 1 week of adaptation, they were randomly divided into 14 groups and divided into three groups: a group fed PBS without inducing arthritis (Control), a group fed PBS to induce arthritis (Model), a group administered P. freudenreichii MJ2-derived surface protein fraction (1 mg / kg / mouse) to induce arthritis (SP), and a group administered Cpn60 (0.1 mg / kg / mouse) to induce arthritis (Cpn60). Each sample was directly injected into DBA / 1 mice orally (Control and Model groups) or intraperitoneally (SP and Cpn60 groups) for 3 weeks before arthritis induction, and arthritis was induced with collagen. Arthritis was induced by injecting type II bovine collagen, emulsified 1:1 with complete Freund's Adjuvant (CFA), into the tail skin for the first immunization. Three weeks later, type II bovine collagen, emulsified 1:1 with incomplete Freund's Adjuvant (IFA), was injected intradermally into the tail skin for the second immunization. After inducing arthritis, the severity of swelling and inflammation was visually evaluated according to the Arthritic score criteria (Table 3 above) and given a score.
[0195] For the arthritis animal model experiment, the effect was evaluated using the surface proteins fraction (SP) isolated from the P. freudenreichiiMJ2 strain, which showed an effect of inhibiting osteoclast differentiation in in vitro evaluation.
[0196]
[0197] As a result, as shown in Figure 19, the group that was administered PBS and induced arthritis showed the most severe arthritis symptoms, the group that was administered SP showed a statistically significant decrease in arthritis symptoms on the 56th day of CIA induction, and the group that was administered Cpn60 showed a statistically significant difference and a decrease in arthritis symptoms on the 50th, 53rd, and 56th days of CIA induction.
[0198]
[0199] <11-2> Analysis of body weight and hepatotoxicity indices in collagen-induced rheumatoid arthritis (CIA) mice
[0200] For each animal experimental group used in the above Example <11-1>, body weight changes were measured at weekly intervals. Compared to the control group, the group in which arthritis was induced by collagen injection showed a significant decrease in body weight, but there was no significant difference in body weight changes between the groups in which arthritis was induced by collagen injection (Table 4).
[0201] Weight change group Initial weight (mg) Final weight (mg) Control 24.278±0.798 27.389±1.438 Model 23.511±1.355 23.267±1.669*** SP 23.667±1.209 23.989±1.801*** Cpn 60 23.100±1.50 323.478±1.138***
[0202] ***p<0.000, compared with the control group
[0203]
[0204] In addition, as shown in Figure 20, the results of measuring AST (aspartate aminotransferase) and ALT (alanine aminotransferase), which are indicators of hepatotoxicity, in serum showed no significant difference between each experimental group. Therefore, these results indicate that SP and Cpn60 used in the present invention do not cause hepatotoxicity in mice within the administration concentration range.
[0205]
[0206] <11-3> Analysis of the effect of administration of 60 kDa chaperonin protein (Cpn60) according to the present invention on bone erosion in a rheumatoid arthritis mouse model
[0207] In order to confirm the symptoms of bone erosion due to rheumatoid arthritis in the mouse groups used in the above example <11-1>, the hind paws of the mice were analyzed using micro-CT.
[0208]
[0209] As a result, as shown in Fig. 21, it was confirmed that bone erosion symptoms were clearly induced in the collagen-induced rheumatoid arthritis model group compared to the control group that did not induce rheumatoid arthritis. As a result of the micro-CT analysis program analysis, it was shown that the volume and surface of the bone erosion area were significantly reduced in the Cpn60 protein administration group of the present invention compared to the rheumatoid arthritis-induced group.
[0210] In addition, the surface / volume ratio was significantly higher in the Cpn60-administered group compared to the rheumatoid arthritis-induced group (model). The structural model index results, used to evaluate the rods and plates of trabecular bone, showed a statistically significant decrease when Cpn60 was administered compared to the rheumatoid arthritis-induced group.
[0211] As a result of performing H&E staining analysis to compare bone erosion and damage of the knee joint, it was found that damage of the knee joint was reduced by administration of the Cpn60 protein of the present invention, and it was found that when Cpn60 protein was administered to rheumatoid arthritis mice, bone erosion and knee joint damage could be alleviated (Fig. 21).
[0212]
[0213] <11-4> Analysis of collagen antigen-specific IgG, IgG1, and IgG2a antibody concentrations in mice induced with collagen-induced rheumatoid arthritis following administration of the 60 kDa chaperonin protein (Cpn60) of the present invention.
[0214] Blood from the mice used in the above Example <11-1> was collected, plasma was separated, and the concentrations of collagen antigen-specific IgG, IgG1, and IgG2a antibodies were measured using the ELISA method. Specifically, mouse type II collagen was coated on an immunoplate at 4°C, and a blocking process was performed at room temperature. Then, the sample and horseradish peroxidase (HRP)-conjugated anti-mouse IgG antibody, anti-IgG1 antibody, and anti-IgG2a antibody were added and reacted for 3 hours. After 3 hours, the substrate was added, the reaction was stopped with 2N H2SO4, and the amount of each IgG antibody in the plasma was measured.
[0215]
[0216] As a result, as shown in Fig. 22, it was confirmed that the production of collagen antigen-specific IgG antibodies in the blood was promoted when arthritis was induced, whereas in the group administered the Cpn60 protein of the present invention, the concentrations of collagen antigen-specific total IgG, IgG1, and IgG2a antibodies were found to be significantly reduced.
[0217]
[0218] <11-5> Analysis of changes in immune response and inflammatory cytokines following administration of the 60 kDa chaperonin protein (Cpn60) of the present invention in mice induced with collagen-induced rheumatoid arthritis
[0219] Blood was collected from the mice used in the above Example <11-1>, and the serum was used to analyze the levels of inflammatory cytokines TNFα and IL-6 for each group using the ELISA method, and the mRNA expression level of IL-17 was analyzed using the quantitative real-time PCR method.
[0220]
[0221] As a result, as shown in Fig. 23, the levels of inflammatory cytokines TNFα, IL-6, and IL-17 were found to be significantly reduced in the group administered Cpn60 of the present invention compared to the rheumatoid arthritis-induced group.
[0222] Therefore, through these results, the inventors of the present invention were able to find out that administration of Cpn60 of the present invention can suppress excessive immune response caused by rheumatoid arthritis and suppress the level of inflammatory cytokines.
[0223]
[0224] <11-6> Analysis of the effect of 60 kDa chaperonin protein (Cpn60) administration on osteoclast differentiation in mice with collagen-induced rheumatoid arthritis.
[0225] Synovial tissue was isolated from the mouse used in the above example <11-1>, and the relative mRNA expression levels of Nfatc1, Cask, and Calcr, factors related to osteoclast differentiation, within the tissue were analyzed using quantitative real-time PCR.
[0226]
[0227] As a result, as shown in Fig. 24, the expression levels of Nfatc1, Cask, and Calcr were found to be significantly increased in the group (model) that induced rheumatoid arthritis compared to the control group (group that did not induce rheumatoid arthritis), whereas the expression levels of Nfatc1, Cask, and Calcr were found to be significantly decreased in the group administered with the Cpn60 protein of the present invention.
[0228] In addition, when the number of TRAP-positive cells (osteoclasts) stained red in the knee joint area by TRAP staining of the knee joint tissue was analyzed, the number of TRAP-positive cells was found to be significantly increased in the rheumatoid arthritis-induced group (model) compared to the control group. Meanwhile, the group administered with the Cpn60 protein of the present invention showed a significant decrease in the number of TRAP-positive cells compared to the rheumatoid arthritis-induced group (see Fig. 25).
[0229] Through these results, the inventors of the present invention were able to find that the extracellular vesicles and Cpn60 protein isolated from the Propionibacterium freudencii MJ2 strain of the present invention can effectively inhibit the differentiation of osteoclasts and improve inflammatory responses, thereby preventing, improving, and treating rheumatoid arthritis.
[0230] The present invention is the result of research conducted through the following national research and development project.
[0231] Assignment Number: 2022R1A2C1010264
[0232] Ministry of Science and ICT
[0233] Project Management (Professional) Institution Name: National Research Foundation of Korea
[0234] Research Project Name: (Science and Engineering) (Type 1-1 (Integrated Type 1)) Mid-career Research
[0235] Research Project Title: Investigating the Function and Mechanism of Propionic Acid Bacteria-Derived Chaperone in Improving Rheumatoid Arthritis
[0236] Contribution rate: 1 / 1
[0237] Project implementation organization: Korea University Industry-Academic Cooperation Foundation
[0238] Research Period: March 1, 2022 - February 28, 2023
[0239]
[0240] The present invention has been described above, focusing on preferred embodiments thereof. Those skilled in the art will appreciate that the present invention can be implemented in modified forms without departing from its essential characteristics. Therefore, the disclosed embodiments should be considered illustrative rather than limiting. The scope of the present invention is set forth in the claims, not the foregoing description, and all differences within the scope equivalent thereto should be construed as being encompassed by the present invention.
Claims
1. A pharmaceutical composition for the prevention or treatment of rheumatoid arthritis, containing as an active ingredient an extracellular vesicle derived from a strain of Propionibacterium freudenreichii or a 60k Da chaperonin protein (Cpn60).
2. In paragraph 1, A pharmaceutical composition for preventing or treating rheumatoid arthritis, characterized in that the Propionibacterium freudenreichii is a strain of Propionibacterium freudenreichii MJ2 (Accession No. KCCM12272P).
3. In paragraph 1, The above composition, Inhibition of expression of factors related to osteoclast differentiation; Inhibition of production of inflammatory cytokines; Inhibition of TRAP (Tartrate-resistant acid phosphatase) activity in osteoclasts; Increased expression of IL-10; Improvement of bone erosion; or A pharmaceutical composition for the prevention or treatment of rheumatoid arthritis, characterized by having an activity of inhibiting the production of collagen antigen-specific IgG, IgG1, and IgG2a antibodies.
4. In paragraph 1, The extracellular vesicles are present in the composition at a concentration of 1 × 10 6 particles / mL to 1 × 10 8 A pharmaceutical composition for preventing or treating rheumatoid arthritis, characterized in that it contains particles / mL in an amount of 100 particles / mL.
5. In paragraph 1, A pharmaceutical composition for preventing or treating rheumatoid arthritis, characterized in that the extracellular vesicles have an average particle diameter of 150 to 200 nm.
6. A food composition for preventing or improving rheumatoid arthritis, containing extracellular vesicles or 60 kDa chaperonin protein (Cpn60) derived from a strain of Propionibacterium freudenreichii as an active ingredient.
7. In paragraph 6, A food composition for preventing or improving rheumatoid arthritis, characterized in that the above Propionibacterium freudenreichii is a strain of Propionibacterium freudenreichii MJ2 (Accession No. KCCM12272P).
8. In paragraph 6, The above composition, Inhibition of expression of factors related to osteoclast differentiation; Inhibition of production of inflammatory cytokines; Inhibition of TRAP (Tartrate-resistant acid phosphatase) activity in osteoclasts; Increased expression of IL-10; Improvement of bone erosion; or A food composition for preventing or improving rheumatoid arthritis, characterized by having an activity of inhibiting the production of collagen antigen-specific IgG, IgG1, and IgG2a antibodies.
9. In paragraph 6, The extracellular vesicles are present in the composition at a concentration of 1 × 10 6 particles / mL to 1 × 10 8 A food composition for preventing or improving rheumatoid arthritis, characterized in that it contains particles / mL in an amount of 100 particles / mL.
10. In paragraph 6, A food composition for preventing or improving rheumatoid arthritis, characterized in that the extracellular vesicles have an average particle diameter of 150 to 200 nm.
Citation Information
Patent Citations
Prophylactic composition for influenza infection
JP2016028033A
Nanovesicles derived from Propionibacterium bacteria and Use thereof
KR1020180006303A
Paint composition with radon blocking functionality
KR1020210087795A
Booth with easy air circulation and sound absorption
KR102532744B1
